Trials / Terminated
TerminatedNCT02279342
the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Yokohama City University Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effects of febuxostat on coronary plaque volume in patients with chronic stable angina and hyperuricemia.
Detailed description
Patients with stable angina and hyperuricemia who undergo percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) are enrolled. Participants will be randomly assigned to one of the two treatment groups. Febuxostat group and A lifestyle modification group. At 8-12 months, routine follow up angiography and IVUS interrogation as well as endothelial function and several bio markers will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Febuxostat | The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8. |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2017-03-31
- Completion
- 2017-03-31
- First posted
- 2014-10-31
- Last updated
- 2017-08-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02279342. Inclusion in this directory is not an endorsement.